Chikungunya virus envelope protein E1-E2 heterodimer (CHIKV E1-E2)

The **Chikungunya virus envelope protein E1-E2 heterodimer** forms the major surface spikes of the Chikungunya virus (CHIKV) and plays a central role in viral entry and pathogenicity. E1 is a class II viral fusion protein that, once unshielded by E2 during the endosomal acidification, mediates membrane fusion between the viral envelope and host cell membrane, allowing release of viral RNA into the cytoplasm[1][6][8]. E2 is the principal receptor-binding protein; it maintains E1 in the pre-fusion state and initially interacts with host cell surface receptors such as Mxra8 and glycosaminoglycans like heparan sulfate[2][3][6]. Together, the E1-E2 complex is essential for both recognizing host cells and mediating the membrane fusion step required for infection. Both proteins are major targets for neutralizing antibodies and candidate vaccine antigens, and experimental therapies focus on blocking their structural transitions or receptor interactions[2][6][8]. Mutations in E1 (such as V156A, K211T, M88L, N20Y) have been shown to modulate infectivity, cell-type specificity, heparin binding, and virulence, highlighting the dynamic interplay between structure, antigenicity, and viral fitness[2][3]. No direct small-molecule inhibitors are approved, but monoclonal antibodies and entry-blocking biologics are active research areas. E1/E2 proteins serve as key biomarkers for infection and vaccine response[2][6]. Their antigenic complexity and mutational plasticity pose challenges for long-term immunological control and therapeutic development.

Other names

Chikungunya virus glycoprotein E1Chikungunya virus glycoprotein E2CHIKV envelope glycoproteinsE1/E2 envelope glycoprotein complex

Inhibition of viral attachment to host cell (by blocking E2); Inhibition of membrane fusion (by blocking E1 fusion loop or trimer formation); Neutralization via antibody binding blocking structural rearrangements needed for entry[2][6]